Sia Daneshmand, MD
Sia Daneshmand, MD, is currently Professor of Urology and Medicine (Oncology) with Clinical Scholar designation and serves as director of urologic oncology, as well as the urologic oncology (SUO) fellowship director at the University of Southern California in Los Angeles. His main clinical interests include bladder cancer, testicular cancer, and advanced kidney cancer.
Articles by Sia Daneshmand, MD
The panel concludes with a discussion on the complexities of interpreting ctDNA positivity in earlier-stage bladder cancer.
The panel considers the adoption of bladder-sparing protocols and the potential of biomarkers to guide risk stratification.
The panel debates the management of high-grade T1 bladder cancer with lymphovascular invasion and variant histology.
The panel pivots to complex considerations in bladder cancer treatment, weighing the promise of IO in BCG-naïve patients.
The panel shares how patient lifestyle, bladder symptoms, and other factors influence intravesical therapy selection.
The panel explores the challenges of delivering bladder-sparing therapies like gem/doce and TAR-200 in real-world settings.
The panel discusses a wave of bladder cancer therapies, including cretostimogene, gem/doce, and AI-driven biomarkers.
Results of the CREST study show that sasanlimab plus BCG improves EFS compared with BCG alone in high-risk NMIBC.
Dr. Daneshmand discusses some of the designs and results of ADVANCED-2, PIVOT-006, ABLE-22, and more.
The ABLE-22 trial evaluates nadofaragene firadenovec alone and in combination for BCG-unresponsive NMIBC.
Dr. Daneshmand provides overviews and updates from three clinical trials involving cretostimogene for high-risk NMIBC.
Dr. Daneshmand discusses the impressive complete response rate and durability of TAR-200 monotherapy for NMIBC.
In the PENELOPE study, TAR-200 showed greater tissue penetration of gemcitabine compared to standard intravesical therapy.
Dr. Daneshmand reviews data from ENVISION on mytomycin for patients with intermediate-risk bladder cancer.
Dr. Daneshmand talks about key studies and exciting developments in bladder cancer from the LUGPA 2024 Annual Meeting.
Dr. Daneshmand shares his thoughts on alternative intravesical therapies in NMIBC and how they compare for efficacy, safety.
Dr. Sia Daneshmand highlights latest advancements in bladder preservation strategies for patients with NMIBC.
Drs. Daneshmand and Wallis highlight two trials in progress in NMIBC: ABLE-41 and PIVOT-006.
The panel conclude with their thoughts on considerations for TURBT and intravesical therapy versus chemoablation.
The panel considers therapies across different risk stratifications, including ATLAS, ENVISION, and BOND-003 studies.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.